Thailand Cannabis Law 2026: Current Rules Explained
This is general information, not legal advice. As of July 2026, Thailand's cannabis framework is medical-only for cannabis flower, and access requires a valid prescription under the PT 33 system.
Thailand cannabis law 2026 in one minute
As of July 2026, cannabis flower in Thailand is regulated as a controlled herb for medical use, not a recreational consumer product. General retail sales and advertising of cannabis flower are prohibited, while medical dispensing remains possible under the prescribed framework. Separately, extracts containing more than 0.2% THC remain Category 5 narcotics and are governed by a different licensing regime.
“Thailand cannabis law in 2026 is a medical-only framework for cannabis flower, with PT 33 prescriptions required for patient access and stricter licensing for operators.”
What changed from 2025 to 2026
The major shift began on 25 June 2025, when the Ministry of Public Health reclassified cannabis flower as a controlled herb under the traditional medicine framework, effective immediately. That move restricted cannabis flower to medical use and prohibited advertising, general sales, and recreational use. In 2026, Thailand added further ministerial rules on both flower licensing and high-THC extracts, tightening who may sell, process, or export under the new compliance model.
The practical effect is that Thailand no longer operates a broad retail cannabis market. Instead, the law now separates flower, which is handled through the controlled-herb medical framework, from extracts, which are treated under narcotics law when THC content exceeds 0.2%.
Who can buy cannabis flower
Cannabis flower is available only through the medical pathway, which means the buyer needs a valid prescription from an authorised practitioner. The system uses PT 33 prescriptions, and the prescription is typically limited to a 30-day supply. This means casual purchase for recreation is not the legal standard in 2026, even for visitors or tourists.
For operators, the key compliance issue is not simply whether the customer is present, but whether the sale is medically justified, documented, and channelled through the right licensed provider. The 2025 notification also requires traceable sourcing from certified cultivation and harvesting standards, which means operators should treat provenance and recordkeeping as core legal obligations.
PT 33 prescriptions and supply limits
PT 33 is the practical gatekeeper for legal flower access. The prescription must come from a qualified practitioner, and the purchase should match the medical purpose and quantity set out in the prescription. The most commonly cited supply cap is a 30-day, 30-gram-style limit in the medical framework, so businesses should avoid assuming open-ended access.
It is more accurate to describe the rule as prescription-based medical access with a short validity window, rather than as a consumer shopping model. That framing also sits better alongside the current advertising restrictions.
What dispensaries and operators must do
Dispensaries that remain active under the new framework must operate more like healthcare-facing premises than lifestyle retail shops. The 2026 updates require stricter licensing conditions, including compliant premises, storage controls, and an appropriate professional presence during operating hours. In practice, this makes staffing and documentation as important as product sourcing.
Operators should also keep dispensing records, source product from certified or compliant farms, and ensure that any sale is tied to the medical system rather than to general retail marketing. The June 2025 notification specifically prohibits cannabis advertising for commercial purposes across platforms, and also restricts online sales and vending-machine sales. Compliance is therefore not just a licensing issue, but a communications one too.
On-site practitioner and recordkeeping
A medical or traditional medicine professional is expected to be present during operating hours in the compliant medical channel. That requirement matters because it turns dispensing into a supervised medical activity, not an unsupervised retail transaction. Operators should also preserve patient-facing and inventory records so they can show lawful sourcing, lawful dispensing, and lawful quantities if inspected.
Sourcing, storage, and licensing
The sourcing side matters as much as the sale side. The 2025 notification refers to certified cultivation and harvesting standards, while the 2026 updates add tighter licensing and premises requirements for those who sell, process, or export. Businesses that treat sourcing as an afterthought are exposed to compliance risk even if they hold a storefront licence.
Cannabis extracts versus flower
Flower and extracts now sit in different regulatory buckets. Cannabis or hemp extracts containing more than 0.2% THC remain Category 5 narcotics, which means they face narcotics-style controls rather than the controlled-herb framework used for flower. That distinction is critical for anyone handling concentrates, oils, or extract-based products.
The 26 March 2026 extract regulation took effect on 26 April 2026 and narrowed who may produce, import, export, sell, or possess those higher-THC extracts. It also created a more restrictive licensing environment for businesses involved in extract activity. The takeaway is simple: flower access is medical-only, while high-THC extracts face a separate narcotics regime.
Penalties and enforcement
Enforcement has become more active as the framework tightened. Public-facing violations such as unlicensed sales, non-medical distribution, or advertising can trigger fines and possible imprisonment under the current approach. Because the rules changed quickly, businesses should assume that older 2022 to 2024 operating habits are no longer safe.
A useful way to read the current environment is that the government is shifting cannabis into a supervised medical compliance model, not a permissive retail one. For any operator, that means licensing, staffing, sourcing, records, and marketing all need to be reviewed together.
What may change next
A broader Cannabis and Hemp Act remains in the legislative pipeline and is intended to consolidate the framework more fully. The draft discussed in July 2026 points to tighter control from cultivation onward and a continued medical-use-only policy direction. Until that bill is enacted, the current rules continue to rely on the 2025 controlled-herb notification and the 2026 ministerial regulations.
FAQ
Is weed legal in Thailand in 2026?
Cannabis flower is not legal for general recreational use in 2026. Legal access is medical-only and requires a valid PT 33 prescription.
Can tourists buy cannabis in Thailand?
Tourists are not exempt from the medical-only framework. In practice, that means no casual retail access and no assumption that prior tourist-era norms still apply.
Are cannabis extracts treated the same as flower?
No. Extracts above 0.2% THC remain Category 5 narcotics and are regulated separately from cannabis flower.
More from BEAZY
- Browse the BEAZY dispensary menu at Sathorn 11
- Inside the BEAZY dispensary
- BEAZY recording studio and sessions
Sources and disclaimer
Sources: Nation Thailand's reporting on the controlled-herb reclassification and the 2026 cannabis and hemp extract rules, and The Star's July 2026 report on the draft Cannabis and Hemp Act. Last verified 9 July 2026. This article is general information, not legal advice, and not cannabis advertising. For your specific situation, consult a qualified Thai legal or medical professional.